ReviewCurrent rheumatology reviews2026
Rheumatoid Arthritis and Secondary Plant Metabolites: An Analysis.
Review in Current rheumatology reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by persistent joint inflammation, progressive joint destruction, and chronic pain. Although modern therapies like disease-modifying antirheumatic medications (DMARDs) can alleviate symptoms, they may also produce side effects. Because of their anti-inflammatory, antioxidant, and immunomodulatory qualities, plant secondary metabolites such as flavonoids, terpenoids, alkaloids, and phenolic acids have attracted attention as prospective RA treatment agents. This review discusses the pathogenesis of RA and provides an overview of various plant secondary metabolites and their biological activities relevant to RA. It highlights preclinical and clinical studies that have investigated the use of plant metabolites in RA management, demonstrating their potential to reduce inflammation, modulate immune responses, and protect joint structures. The review explores the potential molecular targets and mechanisms of action of plant metabolites in RA, including inflammatory mediators, transcription factors, signalling pathways, oxidative stress, immune cell regulation, cell proliferation and apoptosis, cartilage and bone metabolism, and angiogenesis. Additionally, the challenges and considerations in developing plant-based therapies for RA are discussed, such as efficacy and safety, standardization, bioavailability, regulatory approval, and patient compliance. Finally, future perspectives and research directions are outlined, emphasizing the need for further mechanistic studies, preclinical and clinical investigations, formulation strategies, and interdisciplinary collaborations to fully harness the therapeutic potential of plant secondary metabolites in RA management.
Indexed as
Identifiers
40574399What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.